My IGF-1 was 88 on my last blood work
In October 2024, The US FDA Breakthrough Therapy designation is for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate or advanced fibrosis, based on survodutides groundbreaking results from Phase II study
As one analysis aptly put it, we are at the beginning of a global "Weight Management Movement" driven by the "obesity-as-a-disease" theme, which is poised to create a broad and dynamic weight management industry
Image: IlusMedical/Science Photo Library/Getty Images About the Author Julie Corliss, Executive Editor, Harvard Heart Letter About the Reviewer Anahita Dua, MD, MS, MBA, Contributor Disclaimer: As a service to our readers, Harvard Health Publishing provides access to our library of archived content
Early findings show no measurable bone harm The semaglutide plus lifestyle counseling group achieved significantly greater weight loss than the lifestyle counseling-only group
Ingredients Active ingredient: Semaglutide (Semaglutide)